Microcap Ledger Acrivon Therapeutics, Inc. $ACRV
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
This page is still filling in. We publish more sections as filings are processed.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Watertown, MA
- Fiscal year end
- December 31
- Shares outstanding
- 42,853,362 [10-Q 2026-08-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$37.01M | −$35.40M | $41.42M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | — | −$77.91M | −$63.66M | $41.50M | [10-K 2026-03-19] |
| FY ended Dec 2024 | — | −$80.56M | −$65.67M | $39.82M | [10-K 2026-03-19] |
- Quarterly cash burn
- −$17.70M
- Cash runway Estimate
- ~7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 31,136,296 | [10-Q 2024-11-13] |
| 2025-03-24 | 31,351,480 | [10-K 2025-03-27] |
| 2025-05-09 | 31,355,361 | [10-Q 2025-05-14] |
| 2025-08-08 | 31,455,645 | [10-Q 2025-08-13] |
| 2025-11-07 | 31,555,126 | [10-Q 2025-11-13] |
| 2026-03-16 | 38,744,446 | [10-K 2026-03-19] |
| 2026-05-08 | 42,801,729 | [10-Q 2026-05-13] |
| 2026-08-07 | 42,853,362 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2024-04-17; declared effective 2024-04-29 [S-3 2024-04-17]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-05 | Miller Mary | sell | 294 | $1.99 | [4 2026-10-07] |
| 2026-08-31 | Levin Michaela | grant | 30,000 | — | [4 2026-09-02] |
| 2026-08-25 | Blume-Jensen Peter | sell | 14,036 | $2.21 | [4 2026-08-27] |
| 2026-08-18 | Peterson Katharine | sell | 101 | $2.01 | [4 2026-08-20] |
| 2026-08-18 | Miller Mary | sell | 185 | $2.01 | [4 2026-08-20] |
| 2026-08-18 | Gamelin Erick | sell | 400 | $2.01 | [4 2026-08-20] |
| 2026-08-18 | Devroe Eric | sell | 604 | $2.01 | [4 2026-08-20] |
| 2026-08-18 | Blume-Jensen Peter | sell | 1,229 | $2.01 | [4 2026-08-20] |
| 2026-08-18 | Blume-Jensen Peter | sell | 484 | $2.01 | [4 2026-08-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 8-K | Results of operations |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-06-17 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-13 | 8-K | Results of operations |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-04-23 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-03-23 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-03-19 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-03-19 | 10-K | Annual report |
Alerts for $ACRV
Email me when Acrivon Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.